09:08 AM EST, 11/19/2025 (MT Newswires) -- US equity futures posted narrow gains ahead of Wednesday's opening bell as traders looked ahead to Nvidia's ( NVDA ) quarterly earnings and the minutes from the Federal Reserve's most recent monetary policy meeting.

Dow Jones Industrial Average futures were up 0.2%, S&P 500 futures were 0.2% higher, and Nasdaq futures were up 0.3%.

Nvidia ( NVDA ) shares were 1.8% higher pre-bell ahead of the chipmaker's Q3 earnings report due after Wednesday's closing bell.

Oil prices were lower, with front-month global benchmark North Sea Brent crude down 2.6% at $63.18 per barrel and US West Texas Intermediate crude 2.7% lower at $59.01 per barrel.

The policy-setting Federal Open Market Committee is scheduled to release the minutes from its latest meeting at 2 pm ET.

Investors are also closely watching the long-delayed September nonfarm payrolls report, set for release at 8:30 am ET on Thursday, nearly seven weeks behind schedule due to the 43-day federal government shutdown.

In other world markets, Japan's Nikkei closed 0.3% lower, Hong Kong's Hang Seng ended 0.4% lower, and China's Shanghai Composite finished 0.2% higher. Meanwhile, the UK's FTSE 100 was down 0.2%, and Germany's DAX index was 0.2% higher in Europe's early afternoon session.

In equities, Lowe's (LOW) shares were 5.5% higher pre-bell after the company reported higher fiscal Q3 adjusted earnings and sales. TJX (TJX) stock was up 3% after the company reported stronger fiscal Q3 financial results. Kazia Therapeutics ( KZIA ) shares were 42% higher after the company reported late Tuesday that a patient with stage 4 breast cancer treated with paxalisib-pembrolizumab drug combination achieved an initial immune-complete response.

On the losing side, Target ( TGT ) shares were 3% lower after the company reported lower fiscal Q3 adjusted earnings and sales. Agios Pharmaceuticals ( AGIO ) stock was down 49% after the company reported that its treatment candidate for sickle cell disease failed to achieve statistical significance in the primary endpoint of annualized rate of pain crises in a late-stage trial.